1225601

度骨化醇

United States Pharmacopeia (USP) Reference Standard

• 同義詞: (5Z,7E,22E)-9,10-Secoergosta-5,7,10(19),22-tetraene-1α,3β-diol, (5Z,7E,22E)-9,10-Secoergosta-5,7,10(19),22-tetraene-1,3-diol, 1α-Hydroxyergocalciferol, 1α-Hydroxyvitamin D₂, 1α-OHD2, 1-α-Hydroxyvitamin D2, 1-Hydroxyergocalciferol, TSA 840
• 經驗公式（希爾表示法）: C₂₈H₄₄O₂
• CAS號碼: 54573-75-0
• 分子量：: 412.65
• MDL號碼: MFCD00871065
• 分類程式碼代碼: 41116107
• PubChem物質ID: 329749675
• NACRES: NA.24

屬性

• 等級: pharmaceutical primary standard
• API 家族: doxercalciferol
• 製造商／商標名: USP
• 應用: pharmaceutical (small molecule)
• 形式: neat
• SMILES 字串: CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2C(\CCC[C@]12C)=C\C=C3\C[C@@H](O)C[C@H](O)C3=C
• InChI: 1S/C28H44O2/c1-18(2)19(3)9-10-20(4)25-13-14-26-22(8-7-15-28(25,26)6)11-12-23-16-24(29)17-27(30)21(23)5/h9-12,18-20,24-27,29-30H,5,7-8,13-17H2,1-4,6H3/b10-9+,22-11+,23-12-/t19-,20+,24+,25+,26-,27-,28+/m0/s1
• InChI 密鑰: HKXBNHCUPKIYDM-CGMHZMFXSA-N
• 基因資訊: human ... VDR(7421)

描述

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including MSDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.

應用

Doxercalciferol USP reference standard for use in specified quality tests and assays.

Also used to prepare standard, and standard stock solutions for the assay, and impurity analysis in Doxercalciferol by Liquid chromatography in conjunction with UV detector according to the United States Pharmacopeia monograph (USP).

生化／生理作用

Doxercalciferol is a Vitamin D2 analogue, a Vitamin D Receptor Activator (VDRA).

Doxercalciferol is a Vitamin D2 analogue, a Vitamin D Receptor Activator (VDRA). Doxercalciferol acts as a pro-hormone, needing 25-hydroxylation in the liver for bioactivation into 1α, 25-hydroxyvitamin D2. Pivotal studies in adults on dialysis have demonstrated control of secondary hyperparathyroidism that is superior to placebo therapy, without undue suppression of 1st IMA-PTH < 300 pg/mL, or occurrences of hypercalcemia. Doxercalciferol has been shown to be effective in controlling secondary hyperparathyroidism of adult patients with CKD stages 3-4.

Doxercalciferol is a vitamin D₂ analog that acts as a pro-hormone, activated in the liver to 1α,25-dihydroxyvitamin D₂.

Doxercalciferol is a vitamin D₂ analog that acts as a pro-hormone, activated in the liver to 1α,25-dihydroxyvitamin D₂. Despite its relatively low affinity for the vitamin D receptor (VDR) (before activation), it is effective at suppressing expression of the parathyroid hormone (PTH) gene, and appears to act through the VDR.

分析報告

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

其他說明

Sales restrictions may apply.

安全資訊

• 象形圖: GHS06
• 訊號詞: Danger
• 危險聲明: H300
• 防範說明: P264 - P270 - P301 + P310 - P405 - P501
• 危險分類: Acute Tox. 1 Oral
• 儲存類別代碼: 6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials
• 水污染物質分類（WGK）: WGK 3
• 閃點（°F）: Not applicable
• 閃點（°C）: Not applicable